BK0682 Innovative Drugs
- 1289.061
- +3.677+0.29%
Kexon Pharmaceuticals: Passed EU GMP certification
Glonghui, May 5 | Kexon Pharmaceuticals announced that it recently received the “Pharmaceutical GMP Certificate” issued by the Norwegian Medicines Agency in accordance with relevant regulations of the European Medicines Agency. The certified product is paclitaxel for injection (albumin binding type) (5 mg/ml). Injectable paclitaxel (albumin binding) is the mainstream first-line medication recommended by the European Society of Medical Oncology guidelines for the treatment of metastatic pancreatic cancer and non-small cell lung cancer. According to the GMP mutual recognition system among EU member states, passing the GMP certification this time indicates that the production line that has been certified has met EU GMP standards, and the company has paclitaxel (albumin binding) products for injection
Kexing Pharmaceuticals (688136.SH): Repurchased a total of 1.308,200 shares of the company's shares
Gelonghui May 5 丨 Kexon Pharmaceuticals (688136.SH) issued an announcement that the company did not repurchase shares in April 2024. As of April 30, 2024, the company has repurchased a total of 1.3082 million shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.66% of the company's total share capital. The highest price of the repurchase transaction was 16.77 yuan/share, the lowest price was 14.30 yuan/share, and the total amount of capital paid was RMB 199,973 million (not including transaction fees).
Conn Bay (600572.SH): Cumulative repurchase of 51.45 million shares of the company
Glonghui, May 5, 丨 Conn Bay (600572.SH) announced that as of April 30, 2024, the company had repurchased a total of 51.46.45 million shares of the company's shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 2.00% of the company's total share capital. The highest repurchase transaction price was 5.00 yuan/share, the lowest price was 4.08 yuan/share, and the total capital commission used was 245.9663 million yuan (excluding transaction fees such as stamp duty and transaction fees).
Kexon Pharmaceuticals (688136.SH): Paclitaxel for injection (albumin binding type) has passed EU GMP certification
Kexon Pharmaceuticals (688136.SH) issued an announcement. The company recently received from the Norwegian Drug Administration according to the European Drug Administration...
Dongcheng Pharmaceutical (002675): Performance fluctuations due to heparin APIs, innovative nuclear drugs are expected to reap
The 2023 results are lower than our expectations. The company announced the results for the first quarter of 2023 and 2024: in 2023, the company's revenue was 3.28 billion yuan, down 8.6% year on year, in line with our expectations; net profit due to mother 2.1
Express News | Northeast Pharmaceutical: Sun Company obtained registration certificate for injectable azithromycin
Haizheng Pharmaceutical: “Haizheng Dingzhan” can choose to resell
Zhejiang Haizheng Pharmaceutical Co., Ltd. announced that the closing price of the company's stock for 30 consecutive trading days from March 18, 2024 to April 30, 2024 was lower than 80% of the current share conversion price of the company's “Haizheng Transfer”. According to the agreement in the “Transaction Report”, the “Haizheng Ding Transfer” resale clause came into effect.
East China Pharmaceutical (000963): Steady operating performance, medical and aesthetic business maintained a good growth trend
Incident description The company disclosed its 2024 quarterly report. The company achieved operating income of 10.411 billion yuan, an increase of 2.93% over the previous year; realized net profit to mother of 862 million yuan, an increase of 14.18% over the previous year; realized non-recurring deductions
Tonghua Dongbao (600867): First-quarter results met expectations and won the bid for a full range of insulin products
The results for the first quarter of 2024 are in line with our expectations. The company announced 1Q2024 results: the company's revenue was 591 million yuan, down 11.12% year on year, and net profit to mother was 215 million yuan, down 14.28% year on year, after deducting non-compliance
Ruilian New Materials (688550) Company Information Update Report: 2024Q1 performance will pick up sharply year-on-year, and OLED business prospects can be expected
The 2023 performance was under pressure, and OLED business and cost control helped the 2024Q1 performance improve significantly year-on-year. The company released the 2023 Annual Report and 2024 Quarterly Report, with 2023 revenue of 1,208 billion yuan, YoY
Eling Pharmaceutical (002603): The R&D pipeline is rich and non-respiratory products are growing steadily
Incident: Eling Pharmaceutical released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 10.318 billion yuan (-17.67% year-on-year) and net profit of 1,352 billion yuan (year-on-year -42)
Tianshili (600535): Main product growth is steady, operating quality is healthy
Core view On the evening of April 24, the company released its report for the first quarter of 2024, achieving revenue of 2,049 billion yuan, a year-on-year decline of -1.73%; the slowdown in revenue side growth was mainly due to the cold breathing category's base compared to the same period last year
Fosun Pharmaceuticals (600196): The first quarter met expectations and expected marginal improvement
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 10.157 billion yuan, -7% YoY; attributed/deducted non-net profit of RMB610/609 million, respectively, or -38%/-34% YoY. Business
Express News | Hengrui launches GLP-1R/GIPR dual agonist weight loss phase III study
Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business
Sichuan Biokin Pharmaceutical Co.,Ltd.'s (SHSE:688506) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholde
Express News | Hong Kong stocks generally fell by “Pharmacology”. Pharmacovigilance fell by more than 10%. At one point, Yao Ming Biotech and Pharmaceutical Kangde fell by more than 7%.
Ruilian New Materials (688550): Shows that the materials sector was under short-term pressure in the first quarter and is now recovering
Event: On April 28, the company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved total revenue of 1,208 billion yuan, -18.39% year-on-year; net profit of 1.34 billion yuan to mother
JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Climbs 5.8% This Week, Taking Five-year Gains to 79%
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) shareholders might be concerned after seeing the share price drop 13% in the last month. But that doesn't change the fact that the
Beijing Konruns PharmaceuticalLtd's (SHSE:603590) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Beijing Konruns Pharmaceutical Co.,Ltd.'s (SHSE:603590) stock hasn't moved much. Our analysis suggests that this might be because shareholders hav
Jiangsu Jibeier Pharmaceutical (SHSE:688566) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerni